Global Antibody Partnering Terms and Agreements 2014 to 2020 - ResearchAndMarkets.com

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Monday, May 11, 2020
Information
Tags: 
Health, Pharmaceutical, Contract law, Legal documents, Law, Contract, Negotiation, Antibody, Government
⚠generated by AI ↴
Summary
Key Points: 
  • Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms.
  • Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.
  • This report contains over 1,300 links to online copies of actual Antibody deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners.
  • Insight into the terms included in a Antibody agreement, together with real world clause examples


The "Global Antibody Partnering Terms and Agreements 2014-2020" report has been added to ResearchAndMarkets.com's offering.

The Global Antibody Partnering Terms and Agreements 2014 to 2020 report provides comprehensive understanding and unprecedented access to the Antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors Antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:

  • Antibodies
  • Antibody-drug conjugates
  • Monoclonal antibodies
  • Murine mAb
  • Chimeric mAb
  • Humanized mAb
  • Human aAb
  • Polyclonal Antibodies

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report contains over 1,300 links to online copies of actual Antibody deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Key benefits

  • In-depth understanding of Antibody deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Antibody agreements with real life case studies
  • Detailed access to actual Antibody contracts enter into by the leading fifty bigpharma companies
  • Insight into the terms included in a Antibody agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Key Topics Covered:

Chapter 1 - Introduction

Chapter 2 - Trends in antibody dealmaking

2.1. Introduction

2.2. Antibody partnering over the years

2.3. Most active antibody dealmakers

2.4. Antibody partnering by deal type

2.5. Antibody partnering by therapy area

2.6. Deal terms for antibody partnering

2.6.1 Antibody partnering headline values

2.6.2 Antibody deal upfront payments

2.6.3 Antibody deal milestone payments

2.6.4 Antibody royalty rates

Chapter 3 - Leading antibody deals

3.1. Introduction

3.2. Top antibody deals by value

Chapter 4 - Most active antibody dealmakers

4.1. Introduction

4.2. Most active antibody dealmakers

4.3. Most active antibody partnering company profiles

Chapter 5 - Antibody contracts dealmaking directory

5.1. Introduction

5.2. Antibody contracts dealmaking directory

Chapter 6 - Antibody dealmaking by technology type

Chapter 7 - Partnering resource center

7.1. Online partnering

7.2. Partnering events

7.3. Further reading on dealmaking

Companies Mentioned

  • 3SBio
  • 4D Pharma
  • A*STAR Agency for Science
  • Technology and Research
  • A*STAR Singapore Immunology Network
  • Aarhus University Hospital
  • Abbvie
  • Abcam
  • AbCellera
  • AbCheck
  • AbClon
  • Abcuro
  • Ab E Discovery
  • Abeome
  • Abilita Bio
  • Ab Initio
  • ABL Bio
  • Ablexis
  • Ablynx
  • AbMed
  • Abpro
  • Abveris
  • Abzena
  • Acceleron Pharma
  • Accord Healthcare
  • Aceno Biotherapeutics
  • Acerta Pharma
  • Achaogen
  • AC Immune
  • Acticor Biotech
  • Actinium Pharmaceuticals
  • Adagene
  • AdAlta
  • Adaptimmune
  • Adaptive Biotechnologies
  • ADC Therapeutics
  • Adimab
  • Adlai Nortye
  • Aduro BioTech
  • Advanced Biological Laboratories
  • Advanced BioScience Laboratories
  • Advanced Proteome Therapeutics
  • Advantagene
  • Advaxis
  • Aeglea BioTherapeutics
  • Aevi Genomic Medicine
  • AffaMed Therapeutics
  • Affibody
  • Affilogic
  • And Many Many More Companies!

For more information about this report visit https://www.researchandmarkets.com/r/3t95ty

Copyright: 
Copyright Business Wire 2020